First Non-Injectable Octreotide Available for License

Aegis Offers Exclusive License for Patented Octreotide Metered Nasal Spray

San Diego, CA – July 2, 2014 – Aegis announced today that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive octreotide metered nasal spray. Octreotide is a cyclic octapeptide indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in patients in a variety of disease states such as acromegaly, carcinoid tumors, and Vasoactive Intestinal Peptide Tumors (VIPomas).

The patented Aegis Intravail® based octreotide nasal spray is intended as an alternative to the currently marketed subcutaneous injection and depot formulations, while providing equivalent blood levels using a simple metered nasal spray.

Octreotide and related analogs are currently administered either as a three times per day (t.i.d.) subcutaneous injection injectable or monthly depot formulation with annual worldwide revenues exceeding $1.9 billion in 2012 (about $720 million each for the treatment of acromegaly and NeuroEndocrine tumors). The monthly depot formulation requires intramuscular injection using a large diameter (19 gauge) 1 ½ to 2 inch long needle resulting in significant discomfort at the injection site as the needle must remain in place 45 to 120 seconds to deliver the dose. The depot formulation must be compounded immediately before use and must be administered by a trained health care provider, adding additional cost and inconvenience to patients.

As the only non-injectable option for patients seeking to avoid frequent injections and injection site reactions, needlestick injuries, and syringe disposal problems, the non-injectable Aegis nasal spray octreotide formulation is poised to achieve significant market share comprising the bulk of the t.i.d. market and a portion of the long acting formulation.

To view the full product specifications click here and enter your email address in the sign-up box at the bottom of the webpage. For licensing inquiries, please contact Ralph Barry.

About Aegis Therapeutics

Aegis Therapeutics LLC commercializes its patented drug formulation technologies through product-specific licenses. Intravail® drug delivery technology enables non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability.  Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding oxidative damage caused by polysorbate surfactants.

For more information about Aegis, please visit:

Follow Aegis on Twitter, @AegisThera